![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/25/2904125/0/en/Allakos-Announces-Positive-Results-from-its-Ongoing-Phase-1-Trial-of-AK006-in-Healthy-Volunteers-with-AK006-Demonstrating-High-Receptor-Occupancy-on-Mast-Cells-and-a-Favorable-Safe.html
https://www.globenewswire.com/news-release/2024/05/28/2888894/0/en/Allakos-Announces-First-Patient-Dosed-in-Phase-1-Trial-of-AK006-in-Chronic-Spontaneous-Urticaria.html
https://www.globenewswire.com/news-release/2024/05/09/2879144/0/en/Allakos-Provides-Business-Update-and-Reports-First-Quarter-2024-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/14/2846676/0/en/Allakos-Provides-Business-Update-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/26/2835016/0/en/Allakos-Presents-Preclinical-Data-Highlighting-Inhibition-of-MRGPRX2-Mediated-Mast-Cell-Activation-with-AK006-at-AAAAI-2024.html
https://www.globenewswire.com//news-release/2024/02/12/2827417/0/en/Allakos-Announces-Publication-Highlighting-AK006-Mast-Cell-Inhibition.html
https://endpts.com/allakos-halves-workforce-drops-lead-inflammatory-program/
https://investor.allakos.com/news-releases/news-release-details/allakos-announces-phase-2-lirentelimab-trials-atopic-dermatitis
https://www.globenewswire.com//news-release/2023/11/13/2779419/0/en/Allakos-Provides-Business-Update-and-Reports-Third-Quarter-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2023/08/30/2734781/0/en/Allakos-Appoints-Neil-Graham-to-its-Board-of-Directors.html